JP6259245B2 - Peptide having affinity for immunoglobulin G and IgG type antibody adsorbent using the same - Google Patents
Peptide having affinity for immunoglobulin G and IgG type antibody adsorbent using the same Download PDFInfo
- Publication number
- JP6259245B2 JP6259245B2 JP2013211185A JP2013211185A JP6259245B2 JP 6259245 B2 JP6259245 B2 JP 6259245B2 JP 2013211185 A JP2013211185 A JP 2013211185A JP 2013211185 A JP2013211185 A JP 2013211185A JP 6259245 B2 JP6259245 B2 JP 6259245B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- igg
- type antibody
- water
- insoluble carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 87
- 239000003463 adsorbent Substances 0.000 title claims description 55
- 229940027941 immunoglobulin g Drugs 0.000 title description 39
- 210000001124 body fluid Anatomy 0.000 claims description 33
- 239000010839 body fluid Substances 0.000 claims description 33
- 238000000746 purification Methods 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 210000002381 plasma Anatomy 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 230000007717 exclusion Effects 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003446 ligand Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 238000001179 sorption measurement Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000011347 resin Substances 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 125000003277 amino group Chemical group 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
- -1 etc. can be used Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 125000003700 epoxy group Chemical group 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000005373 porous glass Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Substances OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000011209 electrochromatography Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Description
本発明は免疫グロブリンGに対する親和性を有するペプチド及びそれを用いたIgG型抗体吸着材に関する。 The present invention relates to a peptide having affinity for immunoglobulin G and an IgG antibody adsorbent using the peptide.
近年、医学、特に内科学、血液学、免疫学、及び臨床検査学の飛躍的な進歩によって、疾患の原因又は疾患の進行と密接な関係を持っていると考えられる血液中の悪性物質が明らかになりつつある。例えば、血液中に存在する免疫グロブリンG(IgG)を本体とする自己抗体及び免疫複合体は、慢性関節リウマチ、全身性エリテマトーデス、重症筋無力症等、生体免疫機能に関係した自己免疫疾患の原因及び病態の進行と密接な関係を持っていると考えられている。 Recent advances in medicine, especially internal medicine, hematology, immunology, and clinical laboratory science, have revealed malignant substances in blood that are thought to be closely related to the cause of the disease or the progression of the disease. It is becoming. For example, autoantibodies and immune complexes based on immunoglobulin G (IgG) present in blood as a main cause of autoimmune diseases related to biological immune functions such as rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis And is thought to be closely related to the progression of the disease state.
そこで、血液及び血漿等の体液成分から、上記自己抗体及び免疫複合体を特異的に吸着除去することで、上述の疾患の進行を防止し、疾患の症状を軽減せしめ、更には疾患の治癒を早めることが期待されている。体液中の自己抗体及び免疫複合体を除去する技術としては、全血を血球成分と血漿成分とに分離し、血漿中に含まれる上記自己抗体及び免疫複合体を吸着材によって吸着し、除去する方法がある。 Therefore, by specifically adsorbing and removing the autoantibodies and immune complexes from body fluid components such as blood and plasma, the progression of the above-mentioned diseases can be prevented, the symptoms of the diseases can be reduced, and further the healing of the diseases can be achieved. It is expected to be accelerated. As a technique for removing autoantibodies and immune complexes in body fluids, whole blood is separated into blood cell components and plasma components, and the autoantibodies and immune complexes contained in plasma are adsorbed by an adsorbent and removed. There is a way.
従来、このような目的に使用する吸着材としては、水不溶性担体にリガンドとして疎水性アミノ酸であるトリプトファンを固定化した吸着材が知られている(特許文献1)。さらにIgG型抗体と特異的に相互作用することが知られているプロテインA及び抗ヒト免疫グロブリン抗体等の生物由来のIgG型抗体結合性物質、所謂、生物学的リガンドを、水不溶性担体に固定化した吸着材が知られている(非特許文献1)。 Conventionally, as an adsorbent used for such a purpose, an adsorbent in which tryptophan, which is a hydrophobic amino acid, is immobilized as a ligand on a water-insoluble carrier is known (Patent Document 1). Furthermore, biologically derived IgG-type antibody binding substances such as protein A and anti-human immunoglobulin antibodies known to specifically interact with IgG-type antibodies, so-called biological ligands, are immobilized on a water-insoluble carrier. An adsorbed material is known (Non-Patent Document 1).
しかしながら、トリプトファンをリガンドとして水不溶性担体に固定化させた吸着材は、治療効果が認められる一方で、IgG型抗体を吸着する容量が十分に大きいとは言えない。さらに、上記吸着材は病因物質ではないフィブリノーゲン(Fbg)も吸着除去し、選択吸着性が悪いという欠点がある。 However, while an adsorbent in which tryptophan is immobilized on a water-insoluble carrier as a ligand has a therapeutic effect, it cannot be said that the capacity for adsorbing IgG-type antibodies is sufficiently large. Furthermore, the adsorbent has the disadvantage that it also removes fibrinogen (Fbg), which is not a pathogenic substance, and has poor selective adsorption.
一方で、生物学的リガンドの一例であるプロテインAを水不溶性担体に固定化させた吸着材は、IgG型抗体に対して特異的吸着性能を有している(特許文献2)。そのため上記吸着材は、トリプトファンをリガンドとした吸着材が有する上述のような問題を解決可能であると考えられる。しかしながら、これらの生物学的リガンドは一般的に原料の確保が困難で製品コストがかかるという不利な点がある。さらに、上記吸着材を体液に接触させて使用する際、上記生物学的リガンドが体液中に溶出して重大な副作用を生じる危険がある。加えて、上記生物学的リガンドの製造工程で混入する可能性がある未知のウィルス又は病原菌に由来する感染のリスクがあるといった難点も含んでいる。 On the other hand, an adsorbent in which protein A, which is an example of a biological ligand, is immobilized on a water-insoluble carrier has specific adsorption performance for IgG antibodies (Patent Document 2). Therefore, it is considered that the adsorbent can solve the above-described problems of the adsorbent having tryptophan as a ligand. However, these biological ligands generally have the disadvantage that it is difficult to secure raw materials and the product cost is high. Furthermore, when the adsorbent is used in contact with body fluids, there is a risk that the biological ligand will elute into the body fluids and cause serious side effects. In addition, there is a drawback that there is a risk of infection from unknown viruses or pathogens that may be introduced in the manufacturing process of the biological ligand.
近年の分子生物学及び機器分析技術の発展に伴い、タンパク質の詳細な構造情報とその機能解明が飛躍的に進み、巨大なタンパク質の機能を小さなペプチドで達成することが可能となってきている。例えば、ヘリックス・ループ・ヘリックス構造を有し、抗体並みの特異的結合機能を有するペプチドが見出されている。このようなペプチドとして、特許文献3では、顆粒球コロニー刺激因子(G−CSF)受容体に結合する合成ペプチドが報告されている。しかしながら、ヘリックス・ループ・ヘリックス構造を持つ合成ペプチドとIgG型抗体との結合は報告されていない。
With the recent development of molecular biology and instrumental analysis technology, detailed structural information of proteins and their functions have been elucidated, and it has become possible to achieve the functions of huge proteins with small peptides. For example, peptides having a helix-loop-helix structure and a specific binding function similar to antibodies have been found. As such a peptide,
本発明は、上記事情に鑑みてなされたものであり、IgG型抗体を、高い吸着容量で高選択的に吸着することが可能なペプチド、上記ペプチドを用いたIgG型抗体吸着材、その吸着材を充填したIgG型抗体吸着器、及びその吸着器を備える体液浄化デバイスを提供することを課題とする。 The present invention has been made in view of the above circumstances, a peptide capable of highly selectively adsorbing an IgG-type antibody with a high adsorption capacity, an IgG-type antibody adsorbent using the peptide, and an adsorbent thereof It is an object of the present invention to provide an IgG type antibody adsorber filled with, and a body fluid purification device including the adsorber.
本発明者らは、上記課題を解決すべく鋭意検討を行った結果、ヘリックス・ループ・ヘリックス構造を有するある特定のアミノ酸配列のペプチドがIgG型抗体と選択的に結合することを見出した。さらに、本発明者らは、上記ペプチドをIgG型抗体を結合させるためのリガンドとし、上記リガンドが水不溶性担体に固定化されている吸着材が、体液を浄化させるための治療器(体液浄化用治療器、体液浄化デバイス)として、血液、血漿及び血清等の体液中から、自己抗体及び免疫複合体を構成するIgG型抗体を驚くほど高い吸着容量且つ、高選択的に吸着することを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventors have found that a peptide having a specific amino acid sequence having a helix, loop, and helix structure selectively binds to an IgG antibody. Furthermore, the present inventors use a therapeutic device (for body fluid purification) as an adsorbent in which the peptide is used as a ligand for binding an IgG antibody, and the ligand is immobilized on a water-insoluble carrier. As a treatment device, a body fluid purification device), it has been found that IgG antibodies constituting autoantibodies and immune complexes are adsorbed with surprisingly high adsorption capacity and high selectivity from body fluids such as blood, plasma and serum. The present invention has been completed.
すなわち、本発明は以下に関する。
[1]
配列番号1又は配列番号2に記載のアミノ酸配列を有するペプチド。
[2]
配列番号2に記載のアミノ酸配列を有し、前記アミノ酸配列における7番目のシステイン残基と45番目のシステイン残基とが、互いにジスルフィド結合を形成している、[1]に記載のペプチド。
[3]
水不溶性担体と、
上記水不溶性担体に固定されたペプチドと、を含み、
上記ペプチドが[1]又は[2]に記載のペプチドである、IgG型抗体吸着材。
[4]
上記ペプチドが、上記ペプチドが有する少なくとも1つのシステイン残基のメルカプト基によって、直接又はリンカーを介して、上記水不溶性担体に固定化されている、[3]に記載のIgG型抗体吸着材。
[5]
上記ペプチドが、上記ペプチドが有する少なくとも1つのリジン残基の側鎖のアミノ基によって、直接又はリンカーを介して、上記水不溶性担体に固定化されている、[3]に記載のIgG型抗体吸着材。
[6]
上記ペプチドが、上記ペプチドが有する少なくとも1つのグルタミン酸残基又はアスパラギン酸残基の側鎖のカルボキシル基によって、直接又はリンカーを介して、上記水不溶性担体に固定化されている、[3]に記載のIgG型抗体吸着材。
[7]
上記ペプチドが、上記ペプチドのカルボキシ末端のカルボキシル基によって、直接又はリンカーを介して、上記水不溶性担体に固定化されている、[3]に記載のIgG型抗体吸着材。
[8]
上記ペプチドが、上記ペプチドのアミノ末端のアミノ基によって、直接又はリンカーを介して、上記水不溶性担体に固定化されている、[3]に記載のIgG型抗体吸着材。
[9]
上記リンカーがオリゴエチレングリコール又はポリエチレングリコールである、[4]〜[8]のいずれかに記載のIgG型抗体吸着材。
[10]
上記ペプチドが、上記水不溶性担体1mLあたり、0.1〜100μmol固定化されている、[3]〜[9]のいずれかに記載のIgG型抗体吸着材。
[11]
上記水不溶性担体が粒子上の多孔質体であって、上記水不溶性担体の排除限界分子量が15万〜1000万である、[3]〜[10]のいずれかに記載のIgG型抗体吸着材。
[12]
液体を流入させる入口ポートと、上記液体を流出させる出口ポートを有する容器と、
上記容器に充填された[3]〜[11]のいずれかに記載のIgG型抗体吸着材と、を備えるIgG型抗体吸着器。
[13]
[12]に記載のIgG型抗体吸着器を備える体液浄化デバイスであって、
上記IgG型抗体吸着器に流入する液体が血液、血漿、及び血清からなる群から選ばれる体液である、体液浄化デバイス。
That is, the present invention relates to the following.
[1]
A peptide having the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2.
[2]
The peptide according to [1], which has the amino acid sequence set forth in SEQ ID NO: 2 and wherein the seventh cysteine residue and the 45th cysteine residue in the amino acid sequence form a disulfide bond with each other.
[3]
A water-insoluble carrier;
A peptide immobilized on the water-insoluble carrier,
An IgG type antibody adsorbent, wherein the peptide is the peptide according to [1] or [2].
[4]
The IgG-type antibody adsorbent according to [3], wherein the peptide is immobilized on the water-insoluble carrier directly or via a linker by a mercapto group of at least one cysteine residue of the peptide.
[5]
The IgG-type antibody adsorption according to [3], wherein the peptide is immobilized on the water-insoluble carrier directly or via a linker with an amino group in a side chain of at least one lysine residue of the peptide. Wood.
[6]
The peptide according to [3], wherein the peptide is immobilized on the water-insoluble carrier directly or via a linker by a carboxyl group of a side chain of at least one glutamic acid residue or aspartic acid residue of the peptide. IgG type antibody adsorbent.
[7]
The IgG-type antibody adsorbent according to [3], wherein the peptide is immobilized on the water-insoluble carrier directly or via a linker by a carboxyl group at the carboxy terminus of the peptide.
[8]
The IgG-type antibody adsorbent according to [3], wherein the peptide is immobilized on the water-insoluble carrier directly or via a linker by an amino group at the amino terminal of the peptide.
[9]
The IgG-type antibody adsorbent according to any one of [4] to [8], wherein the linker is oligoethylene glycol or polyethylene glycol.
[10]
The IgG-type antibody adsorbent according to any one of [3] to [9], wherein the peptide is immobilized in an amount of 0.1 to 100 μmol per mL of the water-insoluble carrier.
[11]
The IgG-type antibody adsorbent according to any one of [3] to [10], wherein the water-insoluble carrier is a porous body on particles, and the water-insoluble carrier has an exclusion limit molecular weight of 150,000 to 10 million. .
[12]
A container having an inlet port through which a liquid flows and an outlet port through which the liquid flows out;
An IgG type antibody adsorber comprising the IgG type antibody adsorbent according to any one of [3] to [11] filled in the container.
[13]
A body fluid purification device comprising the IgG antibody adsorber according to [12],
A body fluid purification device, wherein the liquid flowing into the IgG antibody adsorber is a body fluid selected from the group consisting of blood, plasma, and serum.
本発明のペプチドはIgG型抗体を、高い吸着容量で高選択的に吸着することが可能である。 The peptide of the present invention can adsorb IgG-type antibodies with high adsorption capacity and high selectivity.
さらに、上記ペプチドの立体構造がヘリックス・ループ・ヘリックス構造であることから、体液中でも安定である。そのため、上記ペプチドを水不溶性担体に固定化させた吸着材は、血漿及び血清等の体液から高い吸着容量でかつ、高い選択性でIgGを吸着させることが可能である。 Furthermore, since the three-dimensional structure of the peptide is a helix, loop, and helix structure, it is stable even in body fluids. Therefore, the adsorbent in which the above peptide is immobilized on a water-insoluble carrier can adsorb IgG with high selectivity and high selectivity from body fluids such as plasma and serum.
以下、本発明について詳細に述べる。以下の実施形態は、本発明を説明するための例示であり、本発明をこの実施の形態のみに限定する趣旨ではない。 The present invention will be described in detail below. The following embodiment is an example for explaining the present invention, and is not intended to limit the present invention to this embodiment alone.
本実施形態における「IgG型抗体」とは、IgGクラスと同様のFc領域を有するタンパク質であれば、タンパク質分子内のFc領域以外の領域が変性、及び/又は、欠損したタンパク質であってもよい。 The “IgG type antibody” in the present embodiment may be a protein in which a region other than the Fc region in the protein molecule is denatured and / or deleted as long as it is a protein having the same Fc region as the IgG class. .
本明細書においては、当該分野の常法に従って、各種アミノ酸残基を一文字表記で記載し、ペプチドのアミノ酸配列はアミノ末端からカルボキシ末端方向へ左から右へ記載する。 In the present specification, various amino acid residues are described in one-letter code according to conventional methods in the field, and the amino acid sequence of the peptide is described from the amino terminus to the carboxy terminus from left to right.
本発明のペプチドは配列番号1(FNMQQQRRFYEALHEAAAAAGGGGGGGNEEQRNAKIKSIRDDC)又は配列番号2(CGFNMQCQRRFYEALHEAAAAAGGGGGGGNEEQRNAKIKSIRDDC)に記載のアミノ酸配列を有する。上記ペプチドはリガンドとして使用しうる。 The peptide of the present invention has the amino acid sequence described in SEQ ID NO: 1 (FNMQQQRRFYEALHEAAAAAGGGGGGGNEEQRNAKIKSIRDDC) or SEQ ID NO: 2 (CGFNMQCQRRFYEALHEAAAAAGGGGGGGNEEEQRNAKIKSIRDDC). The peptide can be used as a ligand.
上記ペプチドは、配列番号1又は配列番号2に記載のアミノ酸配列を欠損無く連続して有していればどのようなペプチドであってもよいが、好ましくは配列番号1又は配列番号2に記載のアミノ酸配列からなるペプチドである。さらに、配列番号2に記載のアミノ酸配列を有し、上記アミノ酸配列における7番目のシステイン残基と45番目のシステイン残基とが、互いにジスルフィド結合を形成していることが好ましい。 The peptide may be any peptide as long as it has the amino acid sequence described in SEQ ID NO: 1 or SEQ ID NO: 2 continuously without any deletion, but preferably the peptide described in SEQ ID NO: 1 or SEQ ID NO: 2 A peptide consisting of an amino acid sequence. Further, it preferably has the amino acid sequence set forth in SEQ ID NO: 2, and the seventh cysteine residue and the 45th cysteine residue in the amino acid sequence preferably form a disulfide bond with each other.
上記ペプチドの全長は、アミノ酸残基で43〜200残基であることが好ましく、アミノ酸残基で43〜100残基であることがより好ましい。 The total length of the peptide is preferably 43 to 200 amino acid residues, and more preferably 43 to 100 amino acid residues.
上記ペプチドのうち非環状のペプチドは、当該技術において、それ自体公知のペプチド合成方法に従って合成することが出来る。例えばFmoc固相合成法、フラグメント縮合法等の液相合成法が挙げられる。操作が簡便である点から、ペプチド合成方法は固相合成法であることが好ましい。また、本発明のペプチドのうち、環状になっているペプチドは、非環状ペプチドを得た後これを環化して得ることができる。 Of the above peptides, acyclic peptides can be synthesized according to peptide synthesis methods known per se in the art. Examples thereof include liquid phase synthesis methods such as Fmoc solid phase synthesis method and fragment condensation method. In view of simple operation, the peptide synthesis method is preferably a solid phase synthesis method. In addition, among the peptides of the present invention, a cyclic peptide can be obtained by obtaining a non-cyclic peptide and then cyclizing it.
非環状ペプチドは、上述の固相合成法及び液相合成法等の化学合成法は勿論、遺伝子工学的手法を用いることでも製造可能である。例えば、上述のアミノ酸配列をコードする塩基配列を有する核酸を適切な発現ベクターに組み込み、得られた発現ベクターによって適切な宿主細胞(例えば哺乳動物細胞、昆虫細胞、大腸菌)を形質転換する。そして、上記宿主細胞をペプチドの発現に適する条件下で培養することによって、培養物からペプチドを得ることが出来る。 Acyclic peptides can be produced not only by chemical synthesis methods such as the above-mentioned solid phase synthesis method and liquid phase synthesis method, but also by genetic engineering techniques. For example, a nucleic acid having a base sequence encoding the amino acid sequence described above is incorporated into an appropriate expression vector, and an appropriate host cell (eg, mammalian cell, insect cell, E. coli) is transformed with the obtained expression vector. Then, the peptide can be obtained from the culture by culturing the host cell under conditions suitable for the expression of the peptide.
上記ペプチドは、水不溶性担体に固定することによって、IgG型抗体吸着材として利用しうる。 The peptide can be used as an IgG-type antibody adsorbent by fixing it to a water-insoluble carrier.
水不溶性担体とは、水に溶けない担体を意味する。 A water-insoluble carrier means a carrier that is insoluble in water.
リガンドを固定化する際に使用する担体としては、親水性の表面を有し、かつリガンドとの間で共有結合を形成させるために利用し得るアミノ基、カルボキシル基、水酸基などの反応性の官能基を有するものが好ましい。また、上記の水不溶性担体は吸着に使用出来る有効表面積が広い多孔性であるもの(多孔質体)が好ましい。 The carrier used for immobilizing the ligand is a reactive functional group such as an amino group, a carboxyl group, or a hydroxyl group that has a hydrophilic surface and can be used to form a covalent bond with the ligand. Those having a group are preferred. The water-insoluble carrier is preferably a porous material having a large effective surface area that can be used for adsorption (porous material).
上記水不溶性担体は、粒子状、繊維状、シート状、中空糸状等の任意の公知の形状を用いることが出来る。リガンドの保持量又は吸着材としての取扱い性を考慮すると、水不溶性担体は粒子状のものが好ましい。 As the water-insoluble carrier, any known shape such as a particle shape, a fiber shape, a sheet shape, and a hollow fiber shape can be used. In consideration of the amount of ligand retained or the handleability as an adsorbent, the water-insoluble carrier is preferably in the form of particles.
球状担体又は、粒子状担体の平均粒径は、25μm〜2500μmであることが好ましい。担体の比表面積と体液との流通性の面から、上記平均粒径は50μm〜1500μmであることがより好ましい。 The average particle size of the spherical carrier or the particulate carrier is preferably 25 μm to 2500 μm. From the viewpoint of the specific surface area of the carrier and the fluidity of the body fluid, the average particle size is more preferably 50 μm to 1500 μm.
使用出来る担体としては、セルロース系ゲル、デキストラン系ゲル、アガロース系ゲル、ポリアクリルアミド系ゲル、多孔質ガラス、ビニルポリマー等の有機または無機の多孔体が使用でき、通常のアフィニティクロマトグラフィーに用いられる担体用の材料は全て用いることが出来る。 As the carrier that can be used, organic or inorganic porous materials such as cellulose gel, dextran gel, agarose gel, polyacrylamide gel, porous glass, vinyl polymer, etc. can be used, and carriers used for ordinary affinity chromatography All materials for can be used.
これら担体を例示すると、旭化成マイクロキャリア(旭化成株式会社製)及びCM−セルロファイン(登録商標)CH(排除限界タンパク質分子量:約3×106、生化学工業株式会社販売)等のセルロース系担体、特公平1−044725号公報に記載の全多孔質活性化ゲル、CM−トヨパール(登録商標)650C(排除限界タンパク質分子量:5×106、東ソー株式会社製)等のポリビニル系担体、CM−トリスアクリルM(CM−Trisacryl M)〔排除限界タンパク質分子量:1×107、スウェーデン国ファルマシア−LKB(Pharmacia−LKB)社製〕等のポリアクリルアミド系担体、及び、セファロースCL−4B(SepharoseCL−4B)〔排除限界タンパク質分子量:2×107、スウェーデン国ファルマシア−LKB(Pharmacia−LKB)社製〕等のアガロース系担体等の有機質担体、並びに、CPG−10−1000〔排除限界タンパク質分子量:1×108、平均細孔径:100nm、米国エレクトローニュークレオニクス(Electro−nucleonics)社製〕等の多孔性ガラス等の無機質担体が挙げられる。 Examples of these carriers are cellulosic carriers such as Asahi Kasei Microcarrier (manufactured by Asahi Kasei Co., Ltd.) and CM-Cellulofine (registered trademark) CH (exclusion limit protein molecular weight: about 3 × 10 6 , sold by Seikagaku Corporation). JP-A-1-044725, a total porous activated gel, a polyvinyl carrier such as CM-Toyopearl (registered trademark) 650C (exclusion limit protein molecular weight: 5 × 10 6 , manufactured by Tosoh Corporation), CM-Tris Polyacrylamide-based carriers such as acrylic M (CM-Triacryl M) [exclusion limit protein molecular weight: 1 × 10 7 , Pharmacia-LKB, Sweden], and Sepharose CL-4B (Sepharose CL-4B) [exclusion limit protein molecular weight: 2 × 10 7, Sul Den Country Pharmacia -LKB (Pharmacia-LKB) Co. Ltd.] organic carriers agarose-based carrier such as, well, CPG-10-1000 [exclusion limit protein molecular weight: 1 × 10 8, the average pore diameter: 100 nm, USA Electro chromatography And inorganic carriers such as porous glass such as those manufactured by Electro-Nucleonics.
上記水不溶性担体は、体液浄化用水不溶性担体であることが好ましい。体液浄化用水不溶性担体とは、吸着材が血液等の体液に接触した場合、体液中に溶け出さない担体であって、タンパク質の非特異吸着が少ない、ブラジキニン産生能が低い、補体活性化能が低い等、血液適合性等の体液適合性が高い担体を意味する。上記体液浄化用水不溶性担体は、ポリビニルアルコールが架橋したもの(架橋化PVA)であることが好ましい。 The water-insoluble carrier is preferably a body-insoluble water-insoluble carrier. A water-insoluble carrier for body fluid purification is a carrier that does not dissolve in body fluids when the adsorbent comes in contact with body fluids such as blood, has little nonspecific adsorption of proteins, has a low ability to produce bradykinin, and has a complement activation ability Means a carrier having high fluid compatibility such as blood compatibility. The water-insoluble carrier for body fluid purification is preferably a crosslinked polyvinyl alcohol (crosslinked PVA).
水不溶性担体としては、粒子状の多孔質体が好ましく、例えば、多孔性重合体粒子を用いることができる。粒子状の多孔質体は、リガンドを固定化できるものである。目的吸着物質であるIgG型抗体の分子量が約15万であることから、粒子状の多孔質体の排除限界分子量(タンパク質)は、15万〜1000万であることが好ましい。最も好ましい排除限界分子量は100万〜500万である。 As the water-insoluble carrier, a particulate porous body is preferable, and for example, porous polymer particles can be used. The particulate porous body can immobilize the ligand. Since the molecular weight of the IgG type antibody that is the target adsorbing substance is about 150,000, the exclusion limit molecular weight (protein) of the particulate porous material is preferably 150,000 to 10 million. The most preferred exclusion limit molecular weight is 1 million to 5 million.
重合体の組成は、ポリアミド系重合体、ポリエステル系重合体、ポリウレタン系重合体及びビニル化合物の重合体等、多孔性構造をとり得る公知の重合体を用いることができる。特に親水性モノマーによって親水化したビニル化合物系多孔性重合体が好ましい結果を与える。 The polymer composition may be a known polymer that can have a porous structure, such as a polyamide polymer, a polyester polymer, a polyurethane polymer, and a vinyl compound polymer. In particular, a vinyl compound-based porous polymer hydrophilized with a hydrophilic monomer gives preferable results.
リガンドの水不溶性担体への担持方法としては、公知の担体活性化方法及び固定化法を用いることができる。例えば、担体がアミノ基又はカルボキシル基を有する場合には、ジシクロヘキシルカルボジイミド等の縮合試薬の存在下で、リガンドと縮合反応させる方法、及び、担体とリガンドとをグルタルアルデヒド等の2個以上の官能基を有する化合物を用いて結合させる方法が挙げられる。また、担体が水酸基を有する場合には、例えば、臭化シアン等のハロゲン化シアンを担体に作用させ、リガンドのアミノ基の部分で反応させる方法、及び、エピクロロヒドリン等のエポキシ基を有する化合物を担体に作用させ、リガンドのアミノ基やメルカプト基の部分で反応させる方法等が挙げられる。また、リガンドがシステインを有する場合には、マレイミド化した担体と反応させることで固定化することが可能である。 As a method for supporting the ligand on the water-insoluble carrier, a known carrier activation method and immobilization method can be used. For example, when the carrier has an amino group or a carboxyl group, a method of performing a condensation reaction with a ligand in the presence of a condensation reagent such as dicyclohexylcarbodiimide, and two or more functional groups such as glutaraldehyde with the carrier and the ligand And a method of bonding using a compound having the above. In addition, when the carrier has a hydroxyl group, for example, a method in which cyanogen halide such as cyanogen bromide acts on the carrier and reacts with the amino group portion of the ligand, and an epoxy group such as epichlorohydrin is included. Examples thereof include a method in which a compound is allowed to act on a carrier and reacted with the amino group or mercapto group of the ligand. When the ligand has cysteine, it can be immobilized by reacting with a maleimidized carrier.
必要に応じて、水不溶性担体とリガンドとの間に任意の長さの分子(リンカー)を導入したものを吸着材として使用することもできる。リンカー分子としては、ポリメチレン鎖、オリゴエチレングリコール鎖、ポリエチレングリコール鎖、ポリアラニン鎖等が挙げられる。例えば、アガロースの水酸基とポリエチレングリコールジグリシジルエーテルの片側のグリシジル基を反応、結合させ、残ったグリシジル基とリガンドを反応、結合させることができる。 If necessary, a material in which a molecule (linker) having an arbitrary length is introduced between the water-insoluble carrier and the ligand can be used as the adsorbent. Examples of the linker molecule include a polymethylene chain, an oligoethylene glycol chain, a polyethylene glycol chain, and a polyalanine chain. For example, the hydroxyl group of agarose and the glycidyl group on one side of polyethylene glycol diglycidyl ether can be reacted and bonded, and the remaining glycidyl group and the ligand can be reacted and bonded.
本実施形態では、ペプチドが、ペプチドが有する少なくとも1つのシステイン残基のメルカプト基によって、直接又はリンカーを介して、水不溶性担体に固定化されていてもよいし、ペプチドが、ペプチドが有する少なくとも1つのリジン残基の側鎖のアミノ基によって、直接又はリンカーを介して、水不溶性担体に固定化されていてもよいし、ペプチドが、ペプチドが有する少なくとも1つのグルタミン酸残基又はアスパラギン酸残基の側鎖のカルボキシル基によって、直接又はリンカーを介して、水不溶性担体に固定化されていてもよい。また、ペプチドが、ペプチドのカルボキシ末端のカルボキシル基によって、直接又はリンカーを介して、水不溶性担体に固定化されていてもよいし、ペプチドが、ペプチドのアミノ末端のアミノ基によって、直接又はリンカーを介して、水不溶性担体に固定化されていてもよい。 In this embodiment, the peptide may be immobilized on a water-insoluble carrier directly or via a linker by a mercapto group of at least one cysteine residue that the peptide has, or the peptide has at least one peptide that the peptide has. It may be immobilized on a water-insoluble carrier directly or through a linker by the amino group of the side chain of one lysine residue, or the peptide has at least one glutamic acid residue or aspartic acid residue of the peptide. It may be immobilized on a water-insoluble carrier directly or via a linker by a side chain carboxyl group. In addition, the peptide may be immobilized on the water-insoluble carrier directly or via a linker by a carboxyl group at the carboxy terminus of the peptide, or the peptide may be directly or via a linker by the amino group at the amino terminus of the peptide. And may be immobilized on a water-insoluble carrier.
水不溶性担体に対するペプチドの固定化量は、少なすぎると吸着能力が低くなる傾向にあり、多すぎても吸着容量の増大は飽和する。よって、水不溶性担体1mLあたり、0.1〜100μmolの範囲が好ましく、より好ましくは1〜50μmolの範囲である。なお、ペプチドの固定化量は、ペプチド導入反応前後の反応溶液の吸光度を紫外可視分光光度計で測定し、反応前後の吸光度の差分に基づいて算出される。 If the amount of the peptide immobilized on the water-insoluble carrier is too small, the adsorption ability tends to be low, and if it is too large, the increase in the adsorption capacity is saturated. Therefore, the range of 0.1 to 100 μmol per 1 mL of water-insoluble carrier is preferable, and the range of 1 to 50 μmol is more preferable. The amount of the peptide immobilized is calculated based on the difference in absorbance before and after the reaction by measuring the absorbance of the reaction solution before and after the peptide introduction reaction with an ultraviolet-visible spectrophotometer.
IgG型抗体吸着材は、液体を流入させる入口ポートと、上記液体を流出させる出口ポートを有する容器内に充填保持されることによって、IgG型抗体吸着器として使用することができる。このようなIgG型抗体吸着器としては、例えば、IgG型抗体吸着材を使用した体外循環モジュールが挙げられる。 The IgG-type antibody adsorbent can be used as an IgG-type antibody adsorber by being filled and held in a container having an inlet port through which a liquid flows and an outlet port through which the liquid flows out. Examples of such an IgG type antibody adsorber include an extracorporeal circulation module using an IgG type antibody adsorbent.
図1はIgG型抗体吸着材を使用した体外循環モジュールの一実施形態を示す模式断面図である。図1に示す体外循環モジュール1は、円筒2の一端開口部に、内側にフィルター3を張ったパッキン4を介して体液を流入させる入口ポート5(導入口)を有するキャップ6をネジ嵌合し、円筒2の他端開口部に内側にフィルター3’を張ったパッキン4’を介して体液を流出させる出口ポート7(導出口)を有するキャップ8をネジ嵌合して容器を形成し、フィルター3及び3’の間隙にIgG型抗体吸着材を充填保持させて吸着材層9を形成してなるものである。体外循環モジュール1は、例えば、自己抗体及び免疫複合体を除去するための体液浄化デバイスとして使用することができる。
FIG. 1 is a schematic cross-sectional view showing an embodiment of an extracorporeal circulation module using an IgG type antibody adsorbent. In the
吸着材層9には、IgG型抗体吸着材を単独で充填してもよく、他の吸着材と混合して充填してもよい。また、IgG型抗体吸着材と他の吸着材とが積層するように充填してもよい。他の吸着材としては、例えば、幅広い吸着能を有する活性炭等を用いることができる。これによって吸着材の相乗効果による広範な臨床効果が期待できる。吸着材層9の容積は、体外循環に用いる場合、50mL〜700mL程度が適当である。
The
体液浄化デバイスを体外循環で用いる場合には、大きく次の二通りの方法がある。一つの方法は、体内から取り出した血液を遠心分離機又は膜型血漿分離器を使用して、血漿成分と血球成分とに分離した後、血漿成分を上記体液浄化デバイスに通過させ、浄化した後、血球成分とあわせて体内に戻す方法である。他の一つの方法は、体内から取り出した血液を直接、上記体液浄化デバイスに通過させ、浄化する方法である。 When using a body fluid purification device for extracorporeal circulation, there are two main methods. One method is to separate the blood taken out from the body into a plasma component and a blood cell component using a centrifuge or a membrane plasma separator, and then pass the plasma component through the body fluid purification device and purify it. It is a method of returning to the body together with blood cell components. Another method is a method in which blood taken out from the body is directly passed through the body fluid purification device for purification.
体液の通液方法としては、臨床上の必要に応じ、あるいは設備の設置状況に応じて、連続的に通液してもよいし、または断続的に通液使用してもよい。 As a method for passing body fluid, it may be continuously passed or used intermittently depending on clinical necessity or according to the installation situation of equipment.
このような本発明のIgG型抗体吸着材は、体液浄化デバイス用IgG型抗体吸着剤としても把握し得る。なお、本発明のIgG型抗体吸着材及びIgG型抗体吸着器は、IgG型自己抗体吸着材及びIgG型自己抗体吸着器として用いてもよい。本明細書において、「自己抗体」とは、自己の細胞又は組織(移植されたものも含む)に対して産生される抗体を意味する。 Such an IgG type antibody adsorbent of the present invention can also be grasped as an IgG type antibody adsorbent for body fluid purification devices. In addition, you may use the IgG type antibody adsorption material and IgG type antibody adsorption device of this invention as an IgG type autoantibody adsorption material and an IgG type autoantibody adsorption device. As used herein, “autoantibody” means an antibody produced against autologous cells or tissues (including transplanted ones).
IgG型抗体吸着材は、装置に充填して治療器として用いられるにとどまらず、免疫グロブリン、自己抗体、免疫グロブリン誘導体、免疫グロブリン複合体等の分離用吸着剤、精製用吸着材及び、これらの測定用基材としても極めて有効に利用できる。 IgG type antibody adsorbent is not only used as a treatment device by filling in an apparatus, but also an adsorbent for separation such as immunoglobulin, autoantibody, immunoglobulin derivative, immunoglobulin complex, adsorbent for purification, and these It can also be used very effectively as a measurement substrate.
以下、実施例によって本発明をさらに詳細に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not limited to these.
(実施例1)
1.ペプチドの合成方法
Fmoc−PAL−PEG−PS樹脂(ライフテクノロジー社製、置換率0.16mol/g)3g(0.48mmol)にN,N−ジメチルホルムアミド(DMF)を加えて十分に膨潤させた。膨潤させた樹脂を含む懸濁液に30%ピペリジン20mLを添加し1分間振とう後、再度、30%ピペリジンを20mL添加して10分間振とうした。上記樹脂をDMFで十分洗浄した後、少量取り出した樹脂に1%2,4,6−トリニトロベンゼンスルホン酸(TNBS)と10%N,N−ジイソプロピルエチルアミン(DIEA)を2μLずつ添加した。5分静置して樹脂が赤く呈色されることを確認することで、Fmoc基が脱保護されアミノ基が露出したと判断した。Fmoc−アミノ酸4.8mmol、O−(6−クロロベンゾトリアゾール−1−イル)−N,N,N’,N’−テトラメチルウロニウムヘキサフルオロホスファート(HCTU)4.8mmol,DIEA9.6mmolの混合液20mLを樹脂に添加し、室温で30分間振とうさせることでアミノ酸を付加した。DMFで樹脂を洗浄後、少量の樹脂に1%TNBSと10%DIEAを2μLずつ添加した、5分静置して樹脂が赤く呈色されないことを確認することで、アミノ基が全て反応したと判断した。5%無水酢酸20mLを樹脂に加え5分間振とうして、未反応のアミノ基をアセチル化した。この工程を繰り返すことで目的のペプチドを合成した。
Example 1
1. Peptide synthesis method N, N-dimethylformamide (DMF) was added to 3 g (0.48 mmol) of Fmoc-PAL-PEG-PS resin (Life Technology, substitution rate 0.16 mol / g) and sufficiently swollen. . After adding 20 mL of 30% piperidine to the suspension containing the swollen resin and shaking for 1 minute, 20 mL of 30% piperidine was added again and shaken for 10 minutes. After thoroughly washing the resin with DMF, 2 μL each of 1% 2,4,6-trinitrobenzenesulfonic acid (TNBS) and 10% N, N-diisopropylethylamine (DIEA) was added to the resin taken out. It was judged that the Fmoc group was deprotected and the amino group was exposed by confirming that the resin was colored in red after standing for 5 minutes. Fmoc-amino acid 4.8 mmol, O- (6-chlorobenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphate (HCTU) 4.8 mmol, DIEA 9.6 mmol Amino acid was added by adding 20 mL of the mixture to the resin and shaking for 30 minutes at room temperature. After washing the resin with DMF, 2 μL each of 1% TNBS and 10% DIEA was added to a small amount of resin and allowed to stand for 5 minutes to confirm that the resin did not turn red, and all amino groups were reacted. It was judged. 20 mL of 5% acetic anhydride was added to the resin and shaken for 5 minutes to acetylate unreacted amino groups. By repeating this process, the target peptide was synthesized.
ペプチド合成した樹脂はジエチルエーテルで洗浄後、乾燥させた。トリフルオロ酢酸(TFA):アニソール:エチルメチルスルフィド:1.2−エタンジチオール=93:3:3:1(体積比)に調整したクリベージ溶液40mLを加え、室温で4時間静置して脱保護及び脱樹脂反応をした。得られた上清に氷冷したジエチルエーテルを加えてペプチドを析出させ、遠心分離して上清を捨てた。得られた沈殿をジエチルエーテルで数回洗浄した後、十分に乾燥させた。得られたペプチドは0.1%TFA水溶液に溶解し、逆相HPLCで目的のペプチドを精製した。 The peptide-synthesized resin was washed with diethyl ether and dried. 40 mL of cleaved solution adjusted to trifluoroacetic acid (TFA): anisole: ethyl methyl sulfide: 1.2-ethanedithiol = 93: 3: 3: 1 (volume ratio) was added and left at room temperature for 4 hours for deprotection. And de-resin reaction. Ice-cooled diethyl ether was added to the resulting supernatant to precipitate the peptide, which was centrifuged and the supernatant was discarded. The obtained precipitate was washed several times with diethyl ether and then sufficiently dried. The obtained peptide was dissolved in 0.1% TFA aqueous solution, and the target peptide was purified by reverse phase HPLC.
次に、精製したペプチドを30mM Tris−HCl(pH 8.5)100mLに一晩かけて滴下しながら撹拌し、分子内ジスルフィド環化させた。反応前のペプチド溶液と反応後のペプチド溶液とに20mM ジチオニトロ安息香酸(DTNB)溶液をそれぞれ5μL添加し、反応後のペプチド溶液が黄色に呈色されないことを確認することで、メルカプト基が全て反応したと判断した。反応溶液から環状化ペプチドを逆相HPLCで精製した。 Next, the purified peptide was stirred dropwise over 100 mL of 30 mM Tris-HCl (pH 8.5) overnight to effect intramolecular disulfide cyclization. By adding 5 μL each of 20 mM dithionitrobenzoic acid (DTNB) solution to the peptide solution before the reaction and the peptide solution after the reaction, and confirming that the peptide solution after the reaction is not colored yellow, all the mercapto groups are reacted. Judged that. The cyclized peptide was purified from the reaction solution by reverse phase HPLC.
最後に、保護していたN末端のシステイン残基を脱保護した。精製したペプチドを1mMとなるように水20mLに溶解させ、濃度が200mMになるようにo−メトキシアミンを上記ペプチド溶液に添加して室温で2日間反応した。反応終了後、逆相HPCLで精製することで目的のペプチドを得た。 Finally, the protected N-terminal cysteine residue was deprotected. The purified peptide was dissolved in 20 mL of water to 1 mM, o-methoxyamine was added to the peptide solution to a concentration of 200 mM, and the reaction was performed at room temperature for 2 days. After completion of the reaction, the desired peptide was obtained by purification with reverse phase HPCL.
2.ペプチド固定化担体の作製方法
ポリ酢酸ビニル製の球状多孔質体(旭硝子株式会社製、平均粒径100μm、排除限界分子量約100万以上、樹脂1mLに充填できる分子量4万のプルランの量が0.20mL/mL以上)18gをジメチルスルホキシド(和光純薬工業株式会社製)180mLに投入し、そこに、エピクロロヒドリン(和光純薬工業株式会社製)137mL、水酸化ナトリウム(和光純薬工業株式会社製)の水溶液(21g/31.5mL)及び水素化ホウ素ナトリウム(和光純薬工業株式会社製)88mgを添加し、30℃で5時間反応させてエポキシ基を導入した。反応後、エポキシ基を導入した球状多孔質体をメタノール(和光純薬工業株式会社製)で洗浄し、その後、純水で洗浄してエポキシ活性化担体を得た。得られた担体は、1.0Mのチオ硫酸ナトリウム水溶液(和光純薬工業株式会社製)2mLと、活性化担体1mLに1%フェノールフタレインエタノール溶液(和光純薬工業株式会社製)2滴を滴下し、80℃で赤色の呈色が確認されなくなるまで0.1Mの塩酸(和光純薬工業株式会社製)を加え、「活性化量(単位樹脂体積量あたりのエポキシ基の物質量)=塩酸濃度(体積モル濃度)×塩酸滴定量(体積量)/樹脂量(体積量)」の式によって導入されたエポキシ基の量を求め、110μmol/mL以上であることを確認した。
2. Preparation method of peptide-immobilized carrier Spherical porous body made of polyvinyl acetate (manufactured by Asahi Glass Co., Ltd., average particle size of 100 μm, exclusion limit molecular weight of about 1 million or more, and the amount of pullulan having a molecular weight of 40,000 that can be filled in 1 mL of resin is 0.00 18 g of 20 mL / mL or more) is charged into 180 mL of dimethyl sulfoxide (Wako Pure Chemical Industries, Ltd.), and 137 mL of epichlorohydrin (Wako Pure Chemical Industries, Ltd.), sodium hydroxide (Wako Pure Chemical Industries, Ltd.) Aqueous solution (21 g / 31.5 mL) and sodium borohydride (Wako Pure Chemical Industries, Ltd.) 88 mg were added and reacted at 30 ° C. for 5 hours to introduce epoxy groups. After the reaction, the spherical porous body into which the epoxy group was introduced was washed with methanol (manufactured by Wako Pure Chemical Industries, Ltd.) and then washed with pure water to obtain an epoxy activated carrier. The obtained carrier was 2 mL of 1.0 M sodium thiosulfate aqueous solution (manufactured by Wako Pure Chemical Industries, Ltd.) and 2 drops of 1% phenolphthalein ethanol solution (manufactured by Wako Pure Chemical Industries, Ltd.) in 1 mL of the activated carrier. Add 0.1 M hydrochloric acid (manufactured by Wako Pure Chemical Industries, Ltd.) until red coloration is not confirmed at 80 ° C., and “activate amount (epoxy group substance amount per unit resin volume) = The amount of the epoxy group introduced by the formula of “hydrochloric acid concentration (volume molar concentration) × hydrochloric acid titration amount (volume amount) / resin amount (volume amount)” was determined and confirmed to be 110 μmol / mL or more.
次に、エポキシ化担体を30mL秤量し、アンモニア水(濃度:28−30%、関東化学株式会社)を45mL加え、40℃で90分間反応することで、エポキシ基をアミノ基に変換した。得られたアミノ化担体は元素分析によって、定量的にエポキシ基からアミノ基となっていることを確認した。 Next, 30 mL of the epoxidized carrier was weighed, 45 mL of aqueous ammonia (concentration: 28-30%, Kanto Chemical Co., Inc.) was added, and the mixture was reacted at 40 ° C. for 90 minutes to convert the epoxy group to an amino group. The obtained aminated carrier was quantitatively confirmed to be an amino group from an epoxy group by elemental analysis.
次に、アミノ化担体を5mL秤量し、ジメチルスルホキシド(DMSO、和光純薬株式会社製)で膨潤させた後、10mMのSuccinimidyl−[(N−maleimidopropionamido)−diethyleneglycol]ester(米国サーモフィッシャーサイエンティフィック社製)のDMSO溶液10mLを加え、30℃で3時間反応させた。反応後、DMSOで洗浄し、その後純水で洗浄することで、マレイミド化担体を得た。 Next, 5 mL of the amination carrier was weighed and swelled with dimethyl sulfoxide (DMSO, manufactured by Wako Pure Chemical Industries, Ltd.), and then 10 mM Succinimidyl-[(N-maleidopropionamido) -diethyleneglycol] ester (American Thermo Fisher Scientific). 10 mL of DMSO solution) was added and reacted at 30 ° C. for 3 hours. After the reaction, it was washed with DMSO and then washed with pure water to obtain a maleimide carrier.
得られたマレイミド化担体を1.5mL秤量し、2.4mMのペプチド(配列番号2のアミノ酸配列からなるペプチドであって、7番目のシステイン残基と45番目のシステイン残基とが、互いにジスルフィド結合を形成しているペプチド)PBS溶液5mLを加えた。その後、37℃で17時間反応させることで、ペプチド中のメルカプト基と担体中のマレイミド基を共有結合させた。反応後、純水で洗浄することで、ペプチド固定化担体を得た。ペプチドの固定化量は、ペプチド導入反応前後の反応溶液の吸光度(202nm)を紫外可視分光光度計で測定し、その吸光度の差分に基づいて算出した。 The obtained maleimidated carrier was weighed in 1.5 mL, and a 2.4 mM peptide (a peptide consisting of the amino acid sequence of SEQ ID NO: 2, wherein the seventh cysteine residue and the 45th cysteine residue were disulfide to each other. Peptide forming bond) 5 mL of PBS solution was added. Then, the mercapto group in a peptide and the maleimide group in a support | carrier were covalently bound by making it react at 37 degreeC for 17 hours. After the reaction, the peptide-immobilized carrier was obtained by washing with pure water. The amount of peptide immobilization was calculated based on the difference in absorbance after measuring the absorbance (202 nm) of the reaction solution before and after the peptide introduction reaction with an ultraviolet-visible spectrophotometer.
3.血漿吸着試験
健常人から採取したCPD加血液(Citrate Phosphate Dextrose加血液)を遠心分離にて血漿分離し、健常人ヒト血漿を得た。次に得られたペプチド固定化担体を0.5mL秤量し、その6倍容の健常人ヒト血漿を加え、37℃で17.5間分振とうさせた。振とう後、遠心分離にてペプチド固定化担体を除き、上澄み血漿中に含まれる血漿タンパク質(IgG、Fbg、アルブミン(Alb)、免疫グロブリンM(IgM))を測定することで、ペプチド固定化担体への吸着率を算出した。
3. Plasma adsorption test CPD-added blood (Citrate Phosphate Dextrose-added blood) collected from healthy individuals was subjected to plasma separation by centrifugation to obtain healthy human plasma. Next, 0.5 mL of the obtained peptide-immobilized carrier was weighed, 6 times its volume of healthy human plasma was added, and the mixture was shaken at 37 ° C. for 17.5. After shaking, the peptide-immobilized carrier is removed by centrifugation, and the plasma protein (IgG, Fbg, albumin (Alb), immunoglobulin M (IgM)) contained in the supernatant plasma is measured to obtain a peptide-immobilized carrier. The adsorption rate to was calculated.
(比較例1)
実施例1で作製したエポキシ化担体を10mL秤量し、46mMのトリプトファン(和光純薬工業株式会社製)炭酸緩衝溶液20mLを加え、50℃で16時間反応させることで、トリプトファンを担体に共有結合させた。反応後、純水で洗浄することでトリプトファン固定化担体を得た。トリプトファンの固定化量は、トリプトファン導入反応前後の反応溶液の吸光度(280nm)を紫外可視分光光度計で測定し、その吸光度の差分に基づいて算出した。このトリプトファン固定化担体を用いて、実施例1と同様の方法で健常人ヒト血漿におけるタンパク質吸着試験を実施した。
(Comparative Example 1)
10 mL of the epoxidized carrier prepared in Example 1 was weighed, 20 mL of 46 mM tryptophan (manufactured by Wako Pure Chemical Industries, Ltd.) carbonate buffer solution was added, and reacted at 50 ° C. for 16 hours to covalently bind tryptophan to the carrier. It was. After the reaction, a tryptophan-immobilized carrier was obtained by washing with pure water. The amount of tryptophan immobilized was calculated based on the difference in absorbance obtained by measuring the absorbance (280 nm) of the reaction solution before and after the tryptophan introduction reaction with an ultraviolet-visible spectrophotometer. Using this tryptophan-immobilized carrier, a protein adsorption test in healthy human plasma was performed in the same manner as in Example 1.
(比較例2)
実施例1で作製したアミノ化担体を用いて、実施例1と同様の方法で健常人ヒト血漿におけるタンパク質吸着試験を実施した。
(Comparative Example 2)
Using the aminated carrier prepared in Example 1, a protein adsorption test in healthy human plasma was performed in the same manner as in Example 1.
実施例1、並びに、比較例1及び2の結果を表1及び図2に示す。
表1に示すように、ペプチド固定化担体を用いた実施例1は、リガンド固定化量がトリプトファンの10分の1以下であるにもかかわらず、高いIgG吸着率を示した。また、トリプトファン固定化担体と比較して、他の血漿タンパク質成分を吸着することなく、IgGに極めて選択的に吸着することも示された。 As shown in Table 1, Example 1 using a peptide-immobilized carrier showed a high IgG adsorption rate despite the ligand immobilization amount being 1/10 or less of tryptophan. In addition, it was also shown to adsorb very selectively to IgG without adsorbing other plasma protein components as compared to the tryptophan-immobilized carrier.
本発明のペプチド及びこれを用いたIgG型抗体吸着材は、例えば、医療産業及び製薬業等で利用可能である。特に、慢性関節リウマチ、全身性エリテマトーデス、重症筋無力症等の自己免疫疾患の病因物質と考えられる自己抗体及び免疫複合体を、高い吸着容量で高選択的に吸着することが可能であることから、自己免疫疾患の治療に有用である。 The peptide of the present invention and the IgG-type antibody adsorbent using the peptide can be used, for example, in the medical industry and the pharmaceutical industry. In particular, it is possible to adsorb autoantibodies and immune complexes, which are thought to be the etiological agent of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis, with high adsorption capacity and high selectivity. Useful in the treatment of autoimmune diseases.
1…体液浄化デバイス(体外循環モジュール)、2…円筒、3、3’…フィルター、4、4’…パッキン、5…入口ポート(体液導入口)、6…キャップ、7…出口ポート(体液導出口)、8…キャップ、9…IgG型抗体吸着材。
DESCRIPTION OF
Claims (7)
前記水不溶性担体に固定されたペプチドと、を含み、
前記ペプチドが、
配列番号1に記載のアミノ酸配列を含むペプチド、又は
配列番号2に記載のアミノ酸配列を含み、前記アミノ酸配列における7番目のシステイン残基と45番目のシステイン残基とが、互いにジスルフィド結合を形成しているペプチドであり、
前記ペプチドが、配列番号1に記載のアミノ酸配列における43番目のシステイン残基のメルカプト基又は配列番号2に記載のアミノ酸配列における1番目のシステイン残基のメルカプト基によって、直接又はリンカーを介して、前記水不溶性担体に固定されている、
IgG型抗体吸着材。 A water-insoluble carrier;
A peptide immobilized on the water-insoluble carrier,
The peptide is
A peptide comprising the amino acid sequence set forth in SEQ ID NO: 1, or
A peptide comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the seventh cysteine residue and the 45th cysteine residue in the amino acid sequence form a disulfide bond with each other;
The peptide is directly or via a linker by the mercapto group of the 43rd cysteine residue in the amino acid sequence shown in SEQ ID NO: 1 or the mercapto group of the 1st cysteine residue in the amino acid sequence shown in SEQ ID NO: 2. Fixed to the water-insoluble carrier,
IgG type antibody adsorbent.
前記容器に充填された請求項1〜5のいずれか一項に記載のIgG型抗体吸着材と、を備えるIgG型抗体吸着器。 A container having an inlet port through which a liquid flows and an outlet port through which the liquid flows out;
An IgG type antibody adsorber comprising the IgG type antibody adsorbent according to any one of claims 1 to 5 filled in the container.
前記IgG型抗体吸着器に流入する液体が血液、血漿、及び血清からなる群から選ばれる体液である、体液浄化デバイス。 A body fluid purification device comprising the IgG type antibody adsorber according to claim 6 ,
A body fluid purification device, wherein the fluid flowing into the IgG antibody adsorber is a body fluid selected from the group consisting of blood, plasma, and serum.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013211185A JP6259245B2 (en) | 2013-10-08 | 2013-10-08 | Peptide having affinity for immunoglobulin G and IgG type antibody adsorbent using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013211185A JP6259245B2 (en) | 2013-10-08 | 2013-10-08 | Peptide having affinity for immunoglobulin G and IgG type antibody adsorbent using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015074626A JP2015074626A (en) | 2015-04-20 |
JP6259245B2 true JP6259245B2 (en) | 2018-01-10 |
Family
ID=52999759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013211185A Active JP6259245B2 (en) | 2013-10-08 | 2013-10-08 | Peptide having affinity for immunoglobulin G and IgG type antibody adsorbent using the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6259245B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6457331B2 (en) * | 2015-04-30 | 2019-01-23 | 株式会社大一商会 | Game machine |
JP6951713B2 (en) * | 2016-03-14 | 2021-10-20 | 公立大学法人大阪 | IgG-binding peptide |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6013763A (en) * | 1996-06-04 | 2000-01-11 | Genentech, Inc. | Peptide variants of protein A |
-
2013
- 2013-10-08 JP JP2013211185A patent/JP6259245B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015074626A (en) | 2015-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6195443B2 (en) | Specific packing material that binds to protein and peptide, and separation method using the same | |
CN102811805B (en) | The specific adsorption agent of conjugated protein and peptide and use the separation method of described adsorbent | |
EP2058335B1 (en) | Biocompatible three dimensional matrix for the immobilization of biological substances | |
EP2021374B1 (en) | Biocompatible three dimensional matrix for the immobilization of biological substances | |
CN102892885B (en) | IgA binding peptide and utilize its purifying of IgA | |
KR20130018699A (en) | Filler for affinity chromatography and method for isolating immunoglobulin | |
DENİZLİ | Purification of antibodies by affinity chromatography | |
EP3669888A1 (en) | Extracorporeal devices for methods for treating diseases associated with anti-neutrophil cytoplasmic antibodies | |
US11186613B2 (en) | Solid-phase support comprising IgG-binding peptide, and method for separating IgG | |
EP3865515A1 (en) | Solid-phase support including igg-binding peptide, and igg separation method | |
JP6328781B2 (en) | Antibody binding polypeptide, antibody binding fusion polypeptide and adsorbing material | |
WO1997026930A1 (en) | Adsorbent for immunoglobulins and complexes thereof, adsorption method, and adsorption device | |
JP6259245B2 (en) | Peptide having affinity for immunoglobulin G and IgG type antibody adsorbent using the same | |
JP4739233B2 (en) | Immunoglobulin purification | |
JP6236278B2 (en) | IgG antibody adsorbent for body fluid purification device | |
JP6864882B2 (en) | IgG type antibody adsorbent carrying a peptide having affinity for immunoglobulin G | |
CN109790202A (en) | Cyclic peptide, affinity chromatography carrier, labelled antibody, antibody drug complex and pharmaceutical preparation | |
CN114588881B (en) | Immunoadsorbent and preparation method thereof | |
WO1988007892A1 (en) | B lymphocyte separating material and body fluid clarifying material | |
KR20180034425A (en) | Methods for isolating affinity carriers and immunoglobulins | |
JPH06261941A (en) | Adsorbent for anti-deoxyribo nucleic acid antibody | |
JP3574471B2 (en) | Anti-epidermal antibody-binding peptide and adsorbent | |
JPS5917354A (en) | Adsorbent for affinity chromatography | |
JPWO2008099855A1 (en) | Autoantibody adsorbent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170724 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171128 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6259245 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |